Comparative assessment of a multiplex micro-chip immunoassay, VaxArray, and meso scale discovery assay for...

Immunoassays for serology have advanced from radio-immunoassays to multiplexed micro-array-based technologies over the past years. Comparative studies can assist users in selecting an assay platform based on its applicability and performance characteristics. This study compared a 9-plex commercial VaxArray Coronavirus SeroAssay (InDevR) and a 10-plex semi-custom Coronavirus SeroAssay (MSD) with a panel of human serum samples. The MSD assay showed superior dynamic range and sensitivity across all coronavirus serotypes, while both assays met accuracy (100 ± 20 %) and precision (%CV < 25 %) criteria. Although both platforms were concordant for anti-SARS-CoV2 IgG measurements, the clinical sensitivity and specificity of the MSD assay were marginally higher than those of VaxArray. Despite VaxArray's shorter total assay time and higher potential for multiplexing and re-readability, it requires improvements in dynamic range, sensitivity, specificity, and automation capabilities for regulated use.